CN103561720A - 己烯雌酚剂型及其在前列腺癌或乳腺癌的治疗中的用途 - Google Patents

己烯雌酚剂型及其在前列腺癌或乳腺癌的治疗中的用途 Download PDF

Info

Publication number
CN103561720A
CN103561720A CN201280011570.XA CN201280011570A CN103561720A CN 103561720 A CN103561720 A CN 103561720A CN 201280011570 A CN201280011570 A CN 201280011570A CN 103561720 A CN103561720 A CN 103561720A
Authority
CN
China
Prior art keywords
sucrose
pharmaceutical composition
matrix
weight
diethylstilbestrol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280011570.XA
Other languages
English (en)
Chinese (zh)
Inventor
J·P·柳
C·K·朱
Z·王
D·S-L·周
R·A·阿科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Royal Pharmaceutical Group
Original Assignee
Nal Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nal Pharmaceuticals Ltd filed Critical Nal Pharmaceuticals Ltd
Publication of CN103561720A publication Critical patent/CN103561720A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280011570.XA 2011-03-03 2012-03-02 己烯雌酚剂型及其在前列腺癌或乳腺癌的治疗中的用途 Pending CN103561720A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/040,143 US8900634B2 (en) 2008-11-03 2011-03-03 Diethylstilbestrol dosage form and methods of treatment using thereof
US13/040,143 2011-03-03
PCT/GB2012/050475 WO2012117257A1 (en) 2011-03-03 2012-03-02 Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer

Publications (1)

Publication Number Publication Date
CN103561720A true CN103561720A (zh) 2014-02-05

Family

ID=45841525

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280011570.XA Pending CN103561720A (zh) 2011-03-03 2012-03-02 己烯雌酚剂型及其在前列腺癌或乳腺癌的治疗中的用途

Country Status (13)

Country Link
US (1) US8900634B2 (https=)
EP (1) EP2680813B1 (https=)
JP (2) JP6059153B2 (https=)
KR (1) KR101865776B1 (https=)
CN (1) CN103561720A (https=)
AU (2) AU2012223023B2 (https=)
BR (1) BR112013022438A2 (https=)
CA (1) CA2827892C (https=)
ES (1) ES2733282T3 (https=)
RU (1) RU2602296C2 (https=)
SG (1) SG192845A1 (https=)
TW (1) TWI548426B (https=)
WO (1) WO2012117257A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899214A (zh) * 2012-10-15 2016-08-24 变色蜥制药公司 用于根治性治疗或姑息性治疗雌性哺乳动物的癌症的磷雌酚
CN105997857A (zh) * 2016-06-29 2016-10-12 冯志清 一种用于治疗猪乳房炎的注射液
CN113133983A (zh) * 2020-01-20 2021-07-20 鲁南制药集团股份有限公司 一种治疗前列腺癌的药物组合物

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8715715B2 (en) * 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
US8900634B2 (en) * 2008-11-03 2014-12-02 Nal Pharmaceuticals, Ltd. Diethylstilbestrol dosage form and methods of treatment using thereof
US20150283155A1 (en) 2012-10-15 2015-10-08 Chamaeleo Pharma Bvba Fosfestrol for use in curative or palliative treatment of prostate cancer
MX2015004761A (es) 2012-10-15 2015-10-12 Chamaeleo Pharma Bvba Sulfestrol para tratar cancer.
NZ727834A (en) 2014-06-24 2020-08-28 Taho Pharmaceuticals Ltd Fast acting orally disintegrating film
MX389336B (es) 2016-11-15 2025-03-20 Klaria Pharma Holding Ab Formulacion farmaceutica.
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
KR101940401B1 (ko) * 2017-06-12 2019-01-21 경상대학교산학협력단 맛이 차폐된 구강붕해필름 및 이의 제조방법
WO2019028457A2 (en) * 2017-08-04 2019-02-07 University Of Houston System FORMULATION OF NANOSUSPENSION OF DIETHYLSTILBESTROL INJECTABLE
GB201808462D0 (en) 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
WO2020030991A1 (en) * 2018-08-09 2020-02-13 Nal Pharmaceutical Group Limited Dosage form for insertion into the mouth

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100112050A1 (en) * 2008-11-03 2010-05-06 Je Phil Ryoo Dosage Form For Insertion Into The Mouth

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
DK2263660T3 (en) 1998-05-18 2018-01-02 Takeda Pharmaceuticals Co Orally disintegrating tablets.
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
US20030147936A1 (en) 2002-02-07 2003-08-07 Velayudhan Sahadevan Prostatic hormonal implants treatment of prostate cancer
PE20060003A1 (es) * 2004-03-12 2006-03-01 Smithkline Beecham Plc Formulacion farmaceutica polimerica para moldear por inyeccion
IL175338A0 (en) * 2006-05-01 2006-09-05 Biota Ltd Orally administrable films and preparation thereof
WO2008045461A2 (en) * 2006-10-11 2008-04-17 Oregon Health & Science University Transdermal diethylstilbestrol for treating prostate cancer
US8105625B2 (en) * 2007-04-05 2012-01-31 University Of Kansas Rapidly dissolving pharmaceutical compositions comprising pullulan
WO2009029543A1 (en) 2007-08-24 2009-03-05 Aegis Therapeutics, Llc Controlled release formulations
US8900634B2 (en) * 2008-11-03 2014-12-02 Nal Pharmaceuticals, Ltd. Diethylstilbestrol dosage form and methods of treatment using thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100112050A1 (en) * 2008-11-03 2010-05-06 Je Phil Ryoo Dosage Form For Insertion Into The Mouth

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
孙忠全等: ""己烯雌酚治疗雄激素非依赖性前列腺癌"", 《第十二届全国、第七届全球华人泌尿外科学术会议论文汇编（上册）》 *
陈虎等: ""己烯雌酚对 Wistar 大鼠乳腺癌发生的干预作用"", 《癌症》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899214A (zh) * 2012-10-15 2016-08-24 变色蜥制药公司 用于根治性治疗或姑息性治疗雌性哺乳动物的癌症的磷雌酚
CN105997857A (zh) * 2016-06-29 2016-10-12 冯志清 一种用于治疗猪乳房炎的注射液
CN113133983A (zh) * 2020-01-20 2021-07-20 鲁南制药集团股份有限公司 一种治疗前列腺癌的药物组合物
CN113133983B (zh) * 2020-01-20 2023-12-12 鲁南制药集团股份有限公司 一种治疗前列腺癌的药物组合物

Also Published As

Publication number Publication date
JP2014506914A (ja) 2014-03-20
JP2017061465A (ja) 2017-03-30
KR20140021587A (ko) 2014-02-20
AU2017203009A1 (en) 2017-05-25
ES2733282T3 (es) 2019-11-28
RU2013144383A (ru) 2015-04-10
WO2012117257A8 (en) 2013-09-19
BR112013022438A2 (pt) 2016-12-06
EP2680813B1 (en) 2019-05-08
CA2827892C (en) 2019-12-03
RU2602296C2 (ru) 2016-11-20
EP2680813A1 (en) 2014-01-08
TW201249484A (en) 2012-12-16
TWI548426B (zh) 2016-09-11
CA2827892A1 (en) 2012-09-07
SG192845A1 (en) 2013-09-30
AU2017203009B2 (en) 2018-07-19
KR101865776B1 (ko) 2018-06-08
US20110189288A1 (en) 2011-08-04
US8900634B2 (en) 2014-12-02
WO2012117257A1 (en) 2012-09-07
JP6059153B2 (ja) 2017-01-11
AU2012223023A1 (en) 2013-09-19
AU2012223023B2 (en) 2017-03-16

Similar Documents

Publication Publication Date Title
AU2017203009B2 (en) Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer
US20070077286A1 (en) Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle
US20190209469A1 (en) Pharmaceutical composition comprising an androgen receptor inhibitor
US9168229B2 (en) Soft gelatin capsules
CH707354A1 (fr) Composition pharmaceutique sous la forme d'une suspension orale comprenant une fraction flavonoïque et de la gomme xanthane.
CN114681432B (zh) 一种丁苯酞组合物及其用途
HK1192153A (en) Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer
US12611377B2 (en) Pharmaceutical composition comprising an androgen receptor inhibitor
ES2717470T3 (es) Formulaciones de obleas y cápsulas con velocidades de disolución aumentadas para fenofibrato
JP2020533369A (ja) チモキノン含有組成物の調製法
CN118252797A (zh) 一种布地奈德黏性口服溶液、制备方法及其应用
CN118021829A (zh) 一种水溶性的维生素d3组合物及其制备方法
US20190008843A1 (en) Pharmaceutical compositions for on demand anticoagulant therapy
BR122025006573A2 (pt) Composição dispersível
BR112020000508B1 (pt) Composição orodispersível e uso de uma composição orodispersível

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1192153

Country of ref document: HK

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160810

Address after: Hongkong, Tongluowan, China

Applicant after: Royal Pharmaceutical Group

Address before: Hongkong Tongluowan China Gloucester Road No. 311 royal building room 2109

Applicant before: Nal Pharmaceuticals Ltd.

CB02 Change of applicant information

Address after: Hongkong Tongluowan China Gloucester Road No. 311 royal building room 2109

Applicant after: Aneng Tai Pharmaceutical Co. Ltd.

Address before: Hongkong, Tongluowan, China

Applicant before: Royal Pharmaceutical Group

COR Change of bibliographic data
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140205

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1192153

Country of ref document: HK